AAAAI & ACAAI GUIDELINES Bundle (free trial)

Anaphylaxis 2016

AAAAI & ACAAI GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/636525

Contents of this Issue

Navigation

Page 3 of 27

4 Diagnosis I. Evaluation and Management of Patients with a History of Anaphylaxis Î Summary Statement (SS) 1: Evaluate any patient who has experienced an episode of anaphylaxis for which the cause is not readily identified to determine the cause and refer to an allergist or immunologist to conduct this evaluation. (R-D) Î SS 2: Supply any patient who has experienced an episode of anaphylaxis for which the allergen cannot be easily and completely avoided with auto-injectable epinephrine (AIE) and instructions as to when and how to administer this injector and emphasize that they should carry 2 AIEs with them at all times. (S-C) Î SS 3: Instruct the patient to wear and/or carry identification denoting his or her condition (eg, MedicAlert, 2193 West Chester Pike, Broomall, PA 19008) and give the patient an anaphylaxis action plan. (S-D) Î SS 4: Individualize avoidance measures taking into consideration factors such as the patient's age, activity, occupation, hobbies, residential conditions, access to medical care, and level of personal anxiety. (R-D) Î SS 5: Use pharmacologic prophylaxis such as glucocorticosteroids and antihistamines in select situations (eg, to prevent recurrent anaphylactic reactions to radiocontrast material (RCM) or to prevent idiopathic anaphylaxis). (R-C) Î SS 6: When necessary, induce a temporary tolerance (desensitization) in patients who have experienced anaphylaxis from medications. (R-C) Î SS 7: Educate patients about hidden allergens and cross-reactivity between various allergens and drugs. (R-C) Î SS 8: Counsel patients at risk for future episodes regarding the use of medications that could worsen an event or complicate therapy (eg, β-adrenergic blockers). (R-C)

Articles in this issue

Archives of this issue

view archives of AAAAI & ACAAI GUIDELINES Bundle (free trial) - Anaphylaxis 2016